CN112057580B

CN112057580B - Traditional Chinese medicine prescription for treating yin deficiency and dryness heat syndrome of pneumoconiosis and application thereof

Info

Publication number: CN112057580B
Application number: CN202010760411.6A
Authority: CN
Inventors: 李建生; 冯素香; 谢洋; 赵虎雷; 赵迪
Original assignee: Henan University of Traditional Chinese Medicine HUTCM
Current assignee: Henan University of Traditional Chinese Medicine HUTCM
Priority date: 2020-07-31
Filing date: 2020-07-31
Publication date: 2024-04-05
Anticipated expiration: 2040-07-31
Also published as: CN112057580A

Abstract

The invention relates to a traditional Chinese medicine prescription for treating yin deficiency and dryness-heat syndrome of pneumoconiosis, which can effectively solve the treatment and medication problem of yin deficiency and dryness-heat syndrome of pneumoconiosis. The technical scheme is that the prescription is composed of the following components in parts by weight: 5-25 parts of dwarf lilyturf tuber, 3-12 parts of American ginseng, 6-18 parts of figwort root, 6-25 parts of snakegourd fruit, 5-20 parts of thunberg fritillary bulb, 6-20 parts of red paeony root, 3-20 parts of turmeric root-tuber, 5-25 parts of aster, 3-20 parts of dried orange peel and 3-15 parts of platycodon root. The traditional Chinese medicine formula for treating the yin deficiency and dryness heat syndrome of pneumoconiosis can be applied to preparing medicines for treating the yin deficiency and dryness heat syndrome of pneumoconiosis, and the formula for treating the yin deficiency and dryness heat syndrome of pneumoconiosis can be prepared into oral preparations such as granules, pills, tablets, capsules, oral liquid, mixture and the like. The invention has scientific and reasonable compatibility and easy production, has the effects of nourishing yin and moistening lung and clearing dryness-heat, is particularly suitable for pneumoconiosis, syndrome differentiation of traditional Chinese medicine as yin deficiency and dryness-heat or syndrome of dryness invading lung, is a great innovation in traditional Chinese medicine, and has remarkable economic and social benefits.

Description

Traditional Chinese medicine prescription for treating yin deficiency and dryness heat syndrome of pneumoconiosis and application thereof

1. Technical field

The invention relates to a medicine, in particular to a traditional Chinese medicine prescription (also called a dust nourishing and lung cleaning prescription) for treating yin deficiency and dryness heat syndrome of pneumoconiosis.

2. Background art

Pneumoconiosis is a collective name for a group of occupational lung diseases mainly comprising diffuse fibrosis of lung tissues due to long-term inhalation of different pathogenic production dust, and the clinical manifestations of pneumoconiosis mainly comprise symptoms of cough, expectoration, chest pain, dyspnea and the like, and the pneumoconiosis is not only the lung diseases but also systemic diseases. The increasing patient population of pneumoconiosis has become a serious public health problem in China. Once pneumoconiosis occurs, the development is progressive, so that dust is harmful to the health of workers, the labor capacity and the life quality of the workers are reduced, and huge economic loss is caused.

So far, effective medicines and measures for treating pneumoconiosis are lacking at home and abroad, and pneumoconiosis prevention and treatment are important social problems and civil problems. In the aspect of occupational disease prevention and treatment, a multidisciplinary collaborator is a key for solving the pneumoconiosis problem. The traditional Chinese medicine has good prospect in treating pneumoconiosis, and related diagnosis and treatment researches are needed to be developed and effective treatment schemes and technologies are needed to be established so as to improve the prevention and treatment level.

3. Summary of the invention

Aiming at the situation, in order to overcome the defects of the prior art, the invention aims to provide a traditional Chinese medicine prescription for treating yin deficiency and dryness heat syndrome of pneumoconiosis, which can effectively solve the treatment problem of pneumoconiosis.

The invention solves the technical scheme that the traditional Chinese medicine formula comprises the following components in parts by weight: 5-25 parts of dwarf lilyturf tuber, 3-12 parts of American ginseng, 6-18 parts of figwort root, 6-25 parts of snakegourd fruit, 5-20 parts of thunberg fritillary bulb, 6-20 parts of red paeony root, 3-20 parts of turmeric root-tuber, 5-25 parts of aster, 3-20 parts of dried orange peel and 3-15 parts of platycodon root; the traditional Chinese medicine formula also comprises the following components by weight: 5-25g of dwarf lilyturf tuber, 3-12g of American ginseng, 6-18g of figwort root, 6-25g of snakegourd fruit, 5-20g of thunberg fritillary bulb, 6-20g of red paeony root, 3-20g of turmeric root-tuber, 5-25g of aster, 3-20g of dried orange peel and 3-15g of platycodon root.

The differentiation of pneumoconiosis in traditional Chinese medicine is yin deficiency and dryness heat syndrome or syndrome of dryness invading lung. Early stage of the disease, the dry and drastic nature of Jinshi attacks the lung and consumes qi to hurt yin. Unlike the dryness-heat of the lung caused by exogenous disease, the pathogenesis is mainly that the lung yin is damaged by dryness, and the lung qi is damaged by yin, and the lung qi is affected by dryness-heat toxin and the lung collaterals blood vessels. For dryness-heat, it is indicated for dryness-heat with the actions of nourishing yin and moistening lung.

In the recipe, ophiopogon root, radix Ophiopogonis, which is sweet and bitter, slightly cold, nourishes yin and clears heat, and promote the production of body fluid and moisten lung, is a monarch drug. Dryness is easy to hurt body fluid, consume qi and hurt yin, and is compatible with American ginseng to tonify qi and nourish yin and assist dwarf lilyturf tuber to nourish yin and promote fluid production and moisten lung; radix scrophulariae nourishes yin and clears heat, as in the cloud of "medical Zhong Shen xi Lu": the radix scrophulariae is black in color, sweet and slightly bitter in taste, cool and multi-liquid, is originally a medicine for clearing and nourishing kidney channels, is hollow in center and white in color, can enter lung to clear dryness-heat of a patient, detoxicate and remove fire, is most suitable for cough due to lung heat, and the American ginseng and the radix scrophulariae are mutually combined to achieve the effects of nourishing yin, clearing heat, tonifying qi and promoting fluid production, and are jointly ministerial medicines. Dust deposits in the lung, failing to disperse and descend the lung, body fluids are not recovered and transformed into phlegm, and dryness-heat hurts the lung, lung yin is insufficient, deficiency fire burns gold, refined liquid is phlegm, and fructus trichosanthis and fritillaria thunbergii are mutually required to be used for clearing heat and resolving phlegm, moistening lung and relieving cough, and are also ministerial drugs. The aster, red paeony root, turmeric root-tuber and dried orange peel are compatible and used as adjuvant drugs, so that the aster is used for moistening lung, resolving phlegm and relieving cough when the lung is damaged by dryness evil in early stage of disease and abnormal cough is caused; when the red paeony root and the radix curcumae are used for cooling blood and activating blood and detoxifying, the yin is damaged by dryness heat, the lung collaterals are blocked by arthralgia, and the blood vessels of the lung collaterals are damaged by heat toxin; dried orange peel regulates qi, invigorates spleen, conditions middle energizer to stop the source of phlegm and prevent cold products from damaging spleen and stomach. For the purpose of guiding the herbs, jie Geng enters lung meridian and mainly directs all herbs to the lung in its guiding formula and exerts its effect of ventilating and activating lung qi, dispelling phlegm and relieving cough.

The traditional Chinese medicine formula for treating the yin deficiency and dryness heat syndrome of pneumoconiosis can be applied to preparation of medicines for treating the yin deficiency and dryness heat syndrome of pneumoconiosis. The prescription for treating the yin deficiency and dryness heat syndrome of pneumoconiosis can be prepared into oral preparations such as granules, pills, tablets, capsules, oral liquid, mixture and the like.

The invention has scientific and reasonable compatibility and easy production, has the effects of nourishing yin and moistening lung and clearing dryness-heat, is particularly suitable for pneumoconiosis, and is especially suitable for syndrome of yin deficiency and dryness-heat or syndrome of dryness invading lung by traditional Chinese medicine differentiation, and is a great innovation in traditional Chinese medicine.

4. Detailed description of the preferred embodiments

The following describes specific embodiments of the present invention in detail with reference to examples.

Example 1

In the specific implementation of the invention, the traditional Chinese medicine formula is prepared from the following traditional Chinese medicines in parts by weight: 5 parts of dwarf lilyturf tuber, 3 parts of American ginseng, 6 parts of figwort root, 6 parts of snakegourd fruit, 5 parts of thunberg fritillary bulb, 6 parts of red paeony root, 3 parts of turmeric root-tuber, 5 parts of aster, 3 parts of dried orange peel and 3 parts of platycodon root.

Example 2

In the specific implementation of the invention, the traditional Chinese medicine formula is prepared from the following traditional Chinese medicines in parts by weight: 25 parts of dwarf lilyturf tuber, 12 parts of American ginseng, 18 parts of figwort root, 25 parts of snakegourd fruit, 20 parts of thunberg fritillary bulb, 20 parts of red paeony root, 20 parts of turmeric root-tuber, 25 parts of aster, 20 parts of dried orange peel and 15 parts of platycodon root.

Example 3

In the specific implementation of the invention, the traditional Chinese medicine formula is prepared from the following traditional Chinese medicines in parts by weight: 12 parts of dwarf lilyturf tuber, 6 parts of American ginseng, 12 parts of figwort root, 15 parts of snakegourd fruit, 9 parts of thunberg fritillary bulb, 9 parts of red paeony root, 9 parts of turmeric root-tuber, 9 parts of aster, 9 parts of dried orange peel and 9 parts of platycodon root.

Example 4

In the specific implementation of the invention, the traditional Chinese medicine formula is prepared from the following traditional Chinese medicines in parts by weight: 5 parts of dwarf lilyturf tuber, 12 parts of American ginseng, 6 parts of figwort root, 25 parts of snakegourd fruit, 9 parts of thunberg fritillary bulb, 9 parts of red paeony root, 3 parts of turmeric root-tuber, 25 parts of aster, 3 parts of dried orange peel and 9 parts of platycodon root.

Example 5

In the specific implementation of the invention, the traditional Chinese medicine formula is prepared from the following traditional Chinese medicines in parts by weight: 5g of dwarf lilyturf tuber, 3g of American ginseng, 6g of figwort root, 6g of snakegourd fruit, 5g of thunberg fritillary bulb, 6g of red paeony root, 3g of turmeric root-tuber, 5g of aster, 3g of dried orange peel and 3g of platycodon root.

Example 6

In the specific implementation of the invention, the traditional Chinese medicine formula is prepared from the following traditional Chinese medicines in parts by weight: 25g of dwarf lilyturf tuber, 12g of American ginseng, 18g of figwort root, 25g of snakegourd fruit, 20g of thunberg fritillary bulb, 20g of red paeony root, 20g of turmeric root-tuber, 25g of aster, 20g of dried orange peel and 15g of platycodon root.

Example 7

In the specific implementation of the invention, the traditional Chinese medicine formula is prepared from the following traditional Chinese medicines in parts by weight: 5g of dwarf lilyturf tuber, 12g of American ginseng, 6g of figwort root, 25g of snakegourd fruit, 9g of thunberg fritillary bulb, 9g of red paeony root, 3g of turmeric root-tuber, 25g of aster, 3g of dried orange peel and 9g of platycodon root.

The traditional Chinese medicine prepared by effectively combining the medicines has the effects of nourishing yin, moistening lung and clearing dryness-heat, is effectively used for treating pneumoconiosis, and is proved by clinical experiments, and the related research data are as follows:

1 object and method

1.1 study subjects 46 cases of pneumoconiosis patients who are accepted and treated by Henan province occupational disease Hospital, first affiliated Hospital of Henan traditional Chinese medicine university, 2 months in 2018 to 4 months in 2020.

1.1.1 Western medicine diagnostic criteria reference the national professional health Standard of the people's republic of China "diagnosis of professional pneumoconiosis" (GBZ 70-2015).

1.1.2 diagnosis and differentiation criteria of Chinese medicine based on literature study, and combining clinical investigation and expert consensus, the diagnosis criteria of Chinese medicine syndrome is formulated. Syndrome of yin deficiency and dryness heat: (1) dyspnea, or shortness of breath; (2) dry cough, or cough with little or no dry sputum; (3) dry mouth or throat; (4) feverish palms and soles or hectic fever after noon; (5) night sweat; (6) dry stool; (7) chest oppression and even chest pain, and hypochondrium; (8) red tongue, or little or no coating, dry or thready and rapid pulse. The composition comprises items (1) and (2)2), and 3 items (3), (4), (5), (6), (7) and (8).

1.1.3 inclusion criteria patients diagnosed with pneumoconiosis in stationary phase based on medical history and related examinations; meets the dialectical standard of traditional Chinese medicine; age 18-75 years old; voluntarily signs an informed consent form.

1.1.4 excluding standard non-detached dust contact and alveolar lavage received within 3 years prior to enrollment; patients with combined active tuberculosis, idiopathic pulmonary fibrosis, bronchial asthma, bronchodilators, pulmonary embolism, chronic respiratory failure, or other severe respiratory diseases; acute exacerbations occur within 1 month prior to enrollment; patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina, acute myocardial infarction, cardiac function grade 3 or above, cerebral apoplexy, cerebral hemorrhage, etc.) are complicated with severe liver and kidney diseases (severe liver diseases refer to liver cirrhosis, portal hypertension and hemorrhage due to varicose veins), and severe kidney diseases include dialysis and kidney transplantation); tumor patients undergoing resection, radiation therapy and chemotherapy within 5 years; combining neuromuscular disease-causing dysplastic patients; severe arthritis was combined; merging severe peripheral vascular disease; pregnant and lactating women; combining severe cognitive and mental abnormalities, and the like; clinical researchers who were taking part in other interventions within 1 month prior to enrollment.

1.2 random and grouping were randomly assigned to 23 cases in each of the test and control groups by the network central random assignment method.

1.3 preparation of medicament 12 parts of dwarf lilyturf tuber, 6 parts of American ginseng, 12 parts of figwort root, 15 parts of snakegourd fruit, 9 parts of thunberg fritillary bulb, 9 parts of red paeony root, 9 parts of turmeric root-tuber, 9 parts of aster, 9 parts of dried orange peel and 9 parts of platycodon root. Decocting the ten materials with 12 times of water for 2 times each for 1 hour, filtering, and concentrating the filtrate into thick paste with the relative density of 1.18-1.22 (60 ℃); drying under reduced pressure, pulverizing into fine powder, adding dextrin (powder: dextrin=3:1), mixing, granulating with 80% ethanol as wetting agent, drying at 60deg.C, and packaging into 10 g/bag.

1.3 intervention both groups of patients were given symptomatic western medicine, the test group was combined with the formula of dust-free lung on the basis of symptomatic treatment, and the control group was given traditional Chinese medicine placebo on the basis of symptomatic treatment. The medicine taking method comprises the following steps: it is administered by soaking in water 3 times per day (10 g each time) for 6 days every week, and stopping administration for 1 day. 3 months is a treatment course, and 2 treatment courses are observed.

1.4 clinical observations index (1) exercise endurance was assessed using a six minute walking distance (6 MWD), with blood pressure, pulse, respiratory rate, spO2 and Borg dyspnea scores recorded before and after each test. The 6MWD was evaluated for 1 outcome before treatment, 12 weeks of treatment, and 24 weeks of treatment; (2) quality of life was assessed using the sheng-georgette respiratory questionnaire (SGRQ), and 1 record each of pre-treatment, 12 weeks of treatment, and 24 weeks of treatment; (3) clinical symptoms were evaluated mainly using the clinical symptom physical sign questionnaire, modified british medical research committee dyspnea scale (mrrc). Outcome assessment was performed 1 time each of pre-treatment, 12 weeks of treatment, and 24 weeks of treatment.

1.5 statistical analysis method the measurement data is firstly subjected to normal test, accords with normal distribution, is described by mean ± standard deviation, adopts two independent sample t test for comparison between groups, repeatedly measures the measurement data for more than 2 times, adopts repeated measurement variance analysis treatment, has no interaction effect between groups and time, directly analyzes main effect, has interaction effect between groups and time, and respectively analyzes independent effects of grouping and time. It is assumed that the test setting P <0.05 is statistically significant.

The counting data are described by frequency, frequency or composition ratio, the comparison between groups is tested by chi-square, assuming that the test is set to P <0.05 has statistical significance.

2 results

2.1 general data study period test and control groups were 4 and 2 incomplete study groups, respectively, and the two groups were comparable in terms of baseline in gender, age, occupation, history, course of disease, complications, etc. See table 1.

2.26MWD

(1) No interaction effect between time and group (f=2.178, p=0.120), with time effect (f=3.203, p=0.046). (2) The MWD of test group 6 was elevated compared to pre-treatment and the MWD of control group 6 was reduced compared to pre-treatment, and neither treatment was statistically significant (P > 0.05) for the 6 month and pre-treatment differences. (3) The comparison of the differences between the two groups was statistically significant (P < 0.05) for 3 months and 6 months. See table 2.

Table 1 general case comparison

Table 2 comparison of two sets of 6MWD

Note that: the P of the composition is less than 0.05 compared with the P before treatment; p <0.05 compared to control group

2.3SGRQ scoring

2.3.1SGRQ symptom score

(1) No interaction effect between time and group (f=0.100, p=0.905), with time effect (f=6.998, p=0.002). (2) Both groups had reduced SGRQ symptom scores compared to pre-treatment; the experimental group had no statistical significance (P > 0.05) for 6 months of treatment versus pre-treatment differences; the control group was statistically significant for the 6 months of treatment versus the pre-treatment differences (P < 0.05). (3) The comparative differences between the two groups were not statistically significant (P > 0.05) for 3 months and 6 months. See table 3.

Table 3 two sets of SGRQ symptom score comparisons

Note that: compared with the prior treatment, the P of the composition is less than 0.05

2.3.2SGRQ Activity score

(1) There is an interaction effect between time and group (f=3.428, p=0.038). (2) Both groups showed reduced SGRQ activity scores compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparison difference between the two groups was statistically not significant (P > 0.05) for 3 months of treatment; the comparison of the differences between the two groups was statistically significant (P < 0.05) for 6 months of treatment. See table 4.

Table 4 two sets of SGRQ activity score comparisons

2.3.3SGRQ impact score

(1) There is an interaction effect between time and group (f=4.818, p=0.011). (2) Both groups had reduced SGRQ impact scores compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparison difference between the two groups was statistically not significant (P > 0.05) for 3 months of treatment; the comparison of the differences between the two groups was statistically significant (P < 0.05) for 6 months of treatment. See table 5.

Table 5 two sets of SGRQ impact score comparisons

2.3.4SGRQ Total score

(1) There is an interaction effect between time and group (f=4.089, p=0.021). (2) The total score was reduced for both groups of SGRQ compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparison difference between the two groups was statistically not significant (P > 0.05) for 3 months of treatment; the comparison of the differences between the two groups was statistically significant (P < 0.05) for 6 months of treatment. See table 6.

Table 6 two sets of SGRQ total score comparisons

2.4mMRC score

(1) No interaction effect between time and group (f=2.698, p=0.074), with time effect (f=3.532, p=0.034). (2) Both groups had reduced mrc scores compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparison difference between the two groups was statistically not significant (P > 0.05) for 3 months of treatment; the comparison of the differences between the two groups was statistically significant (P < 0.05) for 6 months of treatment. See table 7.

Table 7 comparison of two sets of mrrc scores

2.5 clinical symptom score

2.5.1 Total score of clinical symptoms score

(1) There is no interaction effect between time and group (f=2.495, p=0.089), with time effect (f=10.788, p < 0.001). (2) The total score for both sets of clinical symptoms was reduced compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparison difference between the two groups was statistically not significant (P > 0.05) for 3 months of treatment; the comparison of the differences between the two groups was statistically significant (P < 0.05) for 6 months of treatment. See table 8.

Table 8 comparison of total score of two sets of clinical symptom scores

2.5.2 cough score

(1) No interaction effect between time and group (f=2.041, p=0.137), group effect (f=4.888, p=0.033). (2) Both groups had reduced cough scores compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparison difference between the two groups was statistically not significant (P > 0.05) for 3 months of treatment; the comparison of the differences between the two groups was statistically significant (P < 0.05) for 6 months of treatment. See table 9.

Table 9 comparison of cough scores from two groups

2.5.3 sputum-expectoration score

(1) There is an interaction effect between time and group (f=3.167, p=0.048). (2) Both groups had reduced sputum scores compared to pre-treatment; both groups were statistically significant (P > 0.05) for 6 months and prior to treatment. (3) The comparison difference between the two groups was statistically not significant (P > 0.05) for 3 months of treatment; the comparison of the differences between the two groups was statistically significant (P < 0.05) for 6 months of treatment. See table 10.

Table 10 comparison of two groups of phlegm-receiving scores

2.5.4 wheeze score

(1) No interaction effect between time and group (f=1.530, p=0.223), with time effect (f=3.778, p=0.027). (2) Both groups had reduced wheezing scores compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparative differences between the two groups were not statistically significant (P > 0.05) for 3 months and 6 months. See table 11.

Table 11 comparison of the gasp scores of the two groups

2.5.5 chest distress score

(1) There is no interaction effect between time and group (f=0.343, p=0.711), with time effect (f=7.352, p=0.001). (2) Both groups had reduced chest distress scores compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparative differences between the two groups were not statistically significant (P > 0.05) for 3 months and 6 months. See table 12.

Table 12 comparison of chest distress scores

2.5.6 shortness of breath score

(1) No interaction effect between time and group (f=0.321, p=0.727), with time effect (f=5.738, p=0.005). (2) Both groups had reduced shortness of breath scores compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparative differences between the two groups were not statistically significant (P > 0.05) for 3 months and 6 months. See table 13.

Table 13 comparison of two sets of shortness scores

2.5.7 debilitation score

(1) No interaction effect between time and group (f=2.068, p=0.133), with time effect (f=7.372, p=0.001). (2) Both groups had reduced debilitation scores compared to pre-treatment; the experimental group, the 6 months of treatment had statistical significance (P < 0.05) from the pre-treatment differences; the control group had no statistical significance (P > 0.05) for 6 months of treatment versus the pre-treatment difference. (3) The comparative differences between the two groups were not statistically significant (P > 0.05) for 3 months and 6 months. See table 14.

Table 14 comparison of the debilitation scores

2.5.8 cyanosis score

(1) No interaction effect between time and group (f=0.415, p=0.662). (2) Both groups had reduced cyanosis scores compared to pre-treatment; neither group was statistically significant (P > 0.05) for 6 months of treatment versus pre-treatment. (3) The comparative differences between the two groups were not statistically significant (P > 0.05) for 3 months and 6 months. See table 15.

Table 15 comparison of cyanosis scores for the two groups

Conclusion 3

Pneumoconiosis is the main disease species of occupational diseases in China, and has high prevalence rate, high death rate and heavy social and economic burden. So far, no effective medicine and measure for pneumoconiosis are available at home and abroad. The traditional Chinese medicine has good prospect in the aspect of treating pneumoconiosis. In early stage of pneumoconiosis, the dry and drastic substances of Jinshi attack the lung and consume qi to hurt yin, and the pathogenesis is mainly to dryness to hurt lung yin, so it is indicated for treating dryness-heat with the actions of nourishing yin and moistening lung. The clinical trial study is carried out on 46 cases of patients with pneumoconiosis yin deficiency and dryness-heat syndrome by using the prescription for nourishing and cleaning the pneumoconiosis, and obvious effects are obtained.

3.1 exercise endurance

The 6-minute walking test can better reflect the daily life activity of the patient and is widely used for evaluating the functional activity of the patient with cardiopulmonary diseases (heart failure, pulmonary arterial hypertension, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis) so as to determine the total cardiopulmonary reserve. The study uses 6WMD as a main curative effect evaluation index, and results show that compared with a control group, the test group can improve 6MWD of patients, and the difference between the two groups is 73.01 and 95% Cl (7.88-138.15) m. The literature shows that the clinical minimum difference in 6MWD for patients with respiratory diseases (chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis) is 24-45 meters. Compared with the prior treatment, the 6MWD change of the pneumoconiosis patient receiving the pneumoconiosis prescription is larger than the minimum clinical difference value, which indicates that the pneumoconiosis prescription can obviously improve the exercise endurance of the patient.

3.2 quality of life

Pulmonary fibrosis is irreversible in pneumoconiosis patients, and even if pneumoconiosis patients are separated from dust contact, the disease continues to progress and gradually loses work ability. Therefore, improving the quality of life of pneumoconiosis patients is a goal of pneumoconiosis treatment. SGRQ is a measure of the symptoms (measuring respiratory symptoms), activity (measuring impairment of motor ability or physical activity) and impact (measuring the psychosocial impact of disease) of a patient, respectively, with each score and total score being 100 points at the highest, the higher the score, the worse the health-related quality of life. Zhang Meirong et al consider that SGRQ in combination with WHO quality of life assessment profiles can assess the quality of life of pneumoconiosis patients. In this study, SGRQ was used as a main evaluation index for the life evaluation of pneumoconiosis patients. The study data show that the SGRQ activity score, the impact score and the total score of the test group are obviously improved compared with the control group, and the result shows that the pneumoconiosis nourishing and cleaning prescription can obviously improve the life quality of pneumoconiosis patients.

3.3 clinical symptoms

Pneumoconiosis generally occurs over a longer period of time, and even if the patient leaves the dust-contact environment, the condition may progress and aggravate. Cough, hemoptysis, chest pain, dyspnea are the main symptoms of pneumoconiosis, and symptoms such as wheezing, hemoptysis, hypodynamia, anorexia, abdominal distention, constipation and the like. The clinical symptoms are accurately and objectively evaluated, and the method has important guiding function for disease evaluation and treatment scheme adjustment. Therefore, the clinical symptoms should be used as one of the indexes of the curative effect evaluation of the differential treatment of the pneumoconiosis in the traditional Chinese medicine. Compared with a control group, the study data show that the cough, the expectoration, the wheezing, the chest distress and the debilitation symptoms of patients in the test group are obviously changed, and the effect of the dust nourishing and cleaning lung prescription on improving the symptoms of the patients is obvious, so that the survival quality of the patients can be improved by improving the clinical symptoms of the patients.

Dyspnea is the most common and earliest symptom of pneumoconiosis and is associated with the severity of the condition. The mrrc scale is a self-assessment tool commonly used to assess dyspnea in the daily life of chronic respiratory disease. In the study, the clinical curative effect is evaluated by mMRC, and the result shows that the mMRC score of the test group is obviously reduced, which suggests that the prescription for nourishing and cleaning the dust and the lung can improve the dyspnea symptoms of patients.

The prescription for nourishing and cleaning the pneumoconiosis has obvious curative effect on patients with the syndrome of yin deficiency and dryness-heat of the pneumoconiosis, mainly has the advantages of improving exercise endurance and life quality of the patients, improving symptoms such as cough, expectoration, wheezing, chest distress, hypodynamia, dyspnea and the like, is innovation of traditional Chinese medicines, and has obvious economic and social benefits.

Claims

1. A traditional Chinese medicine composition for treating yin deficiency and dryness heat syndrome of pneumoconiosis is characterized by being prepared from the following traditional Chinese medicines in parts by weight: 12-25 parts of dwarf lilyturf tuber, 3-12 parts of American ginseng, 6-18 parts of figwort root, 6-25 parts of snakegourd fruit, 5-20 parts of thunberg fritillary bulb, 6-20 parts of red paeony root, 3-20 parts of turmeric root-tuber, 5-25 parts of aster, 3-20 parts of dried orange peel and 3-15 parts of platycodon root.

2. The traditional Chinese medicine composition for treating yin deficiency and dryness heat syndrome of pneumoconiosis according to claim 1, which is characterized by being prepared from the following traditional Chinese medicines in parts by weight: 25 parts of dwarf lilyturf tuber, 12 parts of American ginseng, 18 parts of figwort root, 25 parts of snakegourd fruit, 20 parts of thunberg fritillary bulb, 20 parts of red paeony root, 20 parts of turmeric root-tuber, 25 parts of aster, 20 parts of dried orange peel and 15 parts of platycodon root.

3. The traditional Chinese medicine composition for treating yin deficiency and dryness heat syndrome of pneumoconiosis according to claim 1, which is characterized by being prepared from the following traditional Chinese medicines in parts by weight: 12 parts of dwarf lilyturf tuber, 6 parts of American ginseng, 12 parts of figwort root, 15 parts of snakegourd fruit, 9 parts of thunberg fritillary bulb, 9 parts of red paeony root, 9 parts of turmeric root-tuber, 9 parts of aster, 9 parts of dried orange peel and 9 parts of platycodon root.

4. The traditional Chinese medicine composition for treating yin deficiency and dryness heat syndrome of pneumoconiosis according to claim 1, which is characterized by being prepared from the following traditional Chinese medicines in parts by weight: 12-25g of dwarf lilyturf tuber, 3-12g of American ginseng, 6-18g of figwort root, 6-25g of snakegourd fruit, 5-20g of thunberg fritillary bulb, 6-20g of red paeony root, 3-20g of turmeric root-tuber, 5-25g of aster, 3-20g of dried orange peel and 3-15g of platycodon root.

5. The traditional Chinese medicine composition for treating yin deficiency and dryness heat syndrome of pneumoconiosis according to claim 1, which is characterized by being prepared from the following traditional Chinese medicines in parts by weight: 25g of dwarf lilyturf tuber, 12g of American ginseng, 18g of figwort root, 25g of snakegourd fruit, 20g of thunberg fritillary bulb, 20g of red paeony root, 20g of turmeric root-tuber, 25g of aster, 20g of dried orange peel and 15g of platycodon root.

6. A traditional Chinese medicine granule for treating yin deficiency and dryness heat syndrome of pneumoconiosis is characterized by being prepared from 12 parts of dwarf lilyturf tuber, 6 parts of American ginseng, 12 parts of figwort root, 15 parts of snakegourd fruit, 9 parts of thunberg fritillary bulb, 9 parts of red paeony root, 9 parts of turmeric root-tuber, 9 parts of aster, 9 parts of dried orange peel and 9 parts of platycodon root, and the preparation method comprises the steps of adding 12 times of water for decocting for 2 times, 1 hour each time, filtering, concentrating the filtrate to a thick paste with relative density of 1.18-1.22 at 60 ℃, drying under reduced pressure, crushing into fine powder, adding dextrin with the weight of 1/3 of the fine powder, uniformly mixing, preparing granules by using 80% ethanol as a wetting agent, drying at 60 ℃, and subpackaging into 10 g/bag to obtain the traditional Chinese medicine granule.

7. Use of a Chinese medicinal composition for treating yin deficiency and dryness-heat syndrome of pneumoconiosis according to any one of claims 1-5 or a Chinese medicinal granule for treating yin deficiency and dryness-heat syndrome of pneumoconiosis according to claim 6 in the preparation of a medicament for treating yin deficiency and dryness-heat syndrome of pneumoconiosis.